Cargando…

Innovation in BCMA CAR-T therapy: Building beyond the Model T

Autologous chimeric antigen receptor T-cell (CAR-T) therapies targeting B-cell maturation antigen (BCMA) have revolutionized the field of multiple myeloma in the same way that the Ford Model T revolutionized the original CAR world a century ago. However, we are only beginning to understand how to im...

Descripción completa

Detalles Bibliográficos
Autores principales: Banerjee, Rahul, Lee, Sarah S., Cowan, Andrew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729952/
https://www.ncbi.nlm.nih.gov/pubmed/36505779
http://dx.doi.org/10.3389/fonc.2022.1070353
_version_ 1784845574912081920
author Banerjee, Rahul
Lee, Sarah S.
Cowan, Andrew J.
author_facet Banerjee, Rahul
Lee, Sarah S.
Cowan, Andrew J.
author_sort Banerjee, Rahul
collection PubMed
description Autologous chimeric antigen receptor T-cell (CAR-T) therapies targeting B-cell maturation antigen (BCMA) have revolutionized the field of multiple myeloma in the same way that the Ford Model T revolutionized the original CAR world a century ago. However, we are only beginning to understand how to improve the efficacy and usability of these cellular therapies. In this review, we explore three automotive analogies for innovation with BCMA CAR-T therapies: stronger engines, better mileage, and hassle-free delivery. Firstly, we can build stronger engines in terms of BCMA targeting: improved antigen binding, tools to modulate antigen density, and armoring to better reach the antigen itself. Secondly, we can improve “mileage” in terms of response durability through ex vivo CAR design and in vivo immune manipulation. Thirdly, we can implement hassle-free delivery through rapid manufacturing protocols and off-the-shelf products. Just as the Model T set a benchmark for car manufacturing over 100 years ago, idecabtagene vicleucel and ciltacabtagene autoleucel have now set the starting point for BCMA CAR-T therapy with their approvals. As with any emerging technology, whether automotive or cellular, the best in innovation and optimization is yet to come.
format Online
Article
Text
id pubmed-9729952
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97299522022-12-09 Innovation in BCMA CAR-T therapy: Building beyond the Model T Banerjee, Rahul Lee, Sarah S. Cowan, Andrew J. Front Oncol Oncology Autologous chimeric antigen receptor T-cell (CAR-T) therapies targeting B-cell maturation antigen (BCMA) have revolutionized the field of multiple myeloma in the same way that the Ford Model T revolutionized the original CAR world a century ago. However, we are only beginning to understand how to improve the efficacy and usability of these cellular therapies. In this review, we explore three automotive analogies for innovation with BCMA CAR-T therapies: stronger engines, better mileage, and hassle-free delivery. Firstly, we can build stronger engines in terms of BCMA targeting: improved antigen binding, tools to modulate antigen density, and armoring to better reach the antigen itself. Secondly, we can improve “mileage” in terms of response durability through ex vivo CAR design and in vivo immune manipulation. Thirdly, we can implement hassle-free delivery through rapid manufacturing protocols and off-the-shelf products. Just as the Model T set a benchmark for car manufacturing over 100 years ago, idecabtagene vicleucel and ciltacabtagene autoleucel have now set the starting point for BCMA CAR-T therapy with their approvals. As with any emerging technology, whether automotive or cellular, the best in innovation and optimization is yet to come. Frontiers Media S.A. 2022-11-24 /pmc/articles/PMC9729952/ /pubmed/36505779 http://dx.doi.org/10.3389/fonc.2022.1070353 Text en Copyright © 2022 Banerjee, Lee and Cowan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Banerjee, Rahul
Lee, Sarah S.
Cowan, Andrew J.
Innovation in BCMA CAR-T therapy: Building beyond the Model T
title Innovation in BCMA CAR-T therapy: Building beyond the Model T
title_full Innovation in BCMA CAR-T therapy: Building beyond the Model T
title_fullStr Innovation in BCMA CAR-T therapy: Building beyond the Model T
title_full_unstemmed Innovation in BCMA CAR-T therapy: Building beyond the Model T
title_short Innovation in BCMA CAR-T therapy: Building beyond the Model T
title_sort innovation in bcma car-t therapy: building beyond the model t
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729952/
https://www.ncbi.nlm.nih.gov/pubmed/36505779
http://dx.doi.org/10.3389/fonc.2022.1070353
work_keys_str_mv AT banerjeerahul innovationinbcmacarttherapybuildingbeyondthemodelt
AT leesarahs innovationinbcmacarttherapybuildingbeyondthemodelt
AT cowanandrewj innovationinbcmacarttherapybuildingbeyondthemodelt